Veterinary Vaccination Schedules and Protocols for Dogs, Cats, and Other Animals

Vaccination schedules and protocols define which biological agents are administered to companion animals, livestock, and exotic species, at what age or interval, and under what clinical conditions. These protocols are shaped by species-specific immunology, regional disease prevalence, regulatory requirements at federal and state levels, and classification frameworks maintained by organizations such as the American Animal Hospital Association (AAHA) and the American Association of Feline Practitioners (AAFP). Understanding the structure of these schedules matters because gaps in vaccination coverage carry documented consequences for individual animal health, herd immunity in shelter and kennel populations, and zoonotic disease transmission to humans. This page covers the foundational definitions, immunological mechanisms, common scheduling scenarios, and the decision boundaries that govern when standard protocols require modification.

Definition and scope

A vaccination protocol is a structured set of clinical instructions that specifies the antigen, route of administration, patient age at first dose, interval between doses in a primary series, and booster frequency. The American Animal Hospital Association (AAHA) publishes canine vaccination guidelines, most recently updated in 2022, while the AAFP maintains the feline equivalent. Both frameworks divide vaccines into two administrative categories:

1. Core vaccines — Recommended for all members of a species regardless of lifestyle, because the diseases targeted pose high morbidity, high mortality, or zoonotic risk. For dogs, core vaccines include canine distemper virus (CDV), canine parvovirus (CPV-2), canine adenovirus-2 (CAV-2), and rabies. For cats, core vaccines include feline panleukopenia virus (FPV), feline herpesvirus-1 (FHV-1), feline calicivirus (FCV), and rabies.
2. Non-core vaccines — Recommended based on assessed individual risk factors such as geographic exposure, lifestyle, and kennel or cattery contact. Examples include Bordetella bronchiseptica, Borrelia burgdorferi (Lyme), leptospirosis, and feline leukemia virus (FeLV).

Rabies vaccination occupies a distinct regulatory tier. Under the National Association of State Public Health Veterinarians (NASPHV) Compendium of Animal Rabies Prevention and Control, all 50 states mandate rabies vaccination for dogs; 46 states also mandate it for cats. Certificate requirements, vaccine brand restrictions, and interval mandates vary by state statute and local ordinance.

Vaccination protocols also apply in livestock and farm animal veterinary services, where regulatory frameworks from the USDA Animal and Plant Health Inspection Service (APHIS) govern biologics licensing under 9 CFR Part 113.

How it works

Vaccination triggers active acquired immunity by presenting the immune system with an antigen — either a killed pathogen, modified live organism, recombinant subunit, or DNA-based construct — without causing disease. The primary series exploits the naive immune system's capacity to generate memory B and T cells. Booster doses at defined intervals stimulate the memory response, maintaining protective antibody titers above threshold levels.

The immunological sequence follows four discrete phases:

1. Antigen recognition — Antigen-presenting cells (APCs) process the vaccine antigen and present peptide fragments to T lymphocytes via MHC class II molecules.
2. Clonal expansion — Activated T-helper cells stimulate B-cell proliferation and differentiation into antibody-secreting plasma cells.
3. Memory formation — Long-lived memory B and T cells are established, enabling rapid secondary response upon re-exposure.
4. Decline and booster trigger — Serum antibody titers decline at species- and antigen-dependent rates. AAHA guidelines note that for core canine vaccines, serologic titer testing may substitute for automatic re-vaccination in adult dogs, provided titers exceed protective thresholds.

Modified live virus (MLV) vaccines typically generate stronger, longer-lasting immunity with a single dose than killed vaccines, which often require adjuvants and multiple doses. However, MLV products are contraindicated in immunocompromised patients and, for certain feline vaccines, in pregnant queens, as noted in AAFP protocols. The distinction between MLV and killed products is a critical decision boundary covered in the section below.

Maternal antibody interference is a primary driver of the multi-dose puppy and kitten series. Maternally derived antibodies (MDA) block vaccine antigens but wane unpredictably between 6 and 16 weeks of age. Administering doses at 3–4 week intervals through 16 weeks ensures at least one dose is received after MDA falls below blocking concentration, per AAHA 2022 guidelines.

Common scenarios

Puppy and kitten primary series — For puppies, AAHA recommends initiating core vaccines at 6–8 weeks, repeating every 3–4 weeks until 16 weeks of age, with a booster at 6–12 months post-series completion, then transition to triennial adult schedules for CDV, CPV-2, and CAV-2. Rabies is administered as a single dose at 12–16 weeks (product-dependent), with a booster at 1 year, then every 1 or 3 years per local statute.

For kittens, AAFP protocols recommend FPV/FHV-1/FCV vaccination beginning at 6–8 weeks, repeated every 3–4 weeks until 16–20 weeks, followed by a booster at 6 months to 1 year, then triennial for indoor cats. FeLV is classified as core for kittens under 1 year old by AAFP, with annual or biennial re-assessment based on risk in adult cats.

Adult dog or cat with unknown history — When vaccination history cannot be verified, AAHA and AAFP both recommend treating the patient as unvaccinated. A 2-dose primary series of MLV core vaccines, 3–4 weeks apart, is administered, followed by standard adult boosters.

Shelter and kennel settings — High-density housing accelerates transmission of respiratory and enteric pathogens. The Association of Shelter Veterinarians (ASV) Guidelines for Standards of Care recommend administering core vaccines at intake, prior to or at the time of housing, including intranasal Bordetella for dogs. This context is also addressed in animal shelter and humane society veterinary programs.

Exotic and zoo species — Protocols for ferrets, rabbits, reptiles, and zoological specimens fall outside standard canine/feline frameworks and are managed by board-certified specialists in exotic animal medicine. Ferrets are subject to USDA-licensed rabies and distemper vaccines approved for mustelids. Further detail appears in exotic and zoo animal veterinary care.

Equine vaccination — The American Association of Equine Practitioners (AAEP) publishes annually updated guidelines classifying equine vaccines as core (Eastern/Western equine encephalomyelitis, West Nile virus, tetanus, rabies) and risk-based (influenza, rhinopneumonitis, strangles). These are detailed under equine veterinary services.

Decision boundaries

Several clinical and regulatory factors determine when a standard protocol must be modified or escalated to specialist evaluation:

Immunocompromised patients — Cats with feline immunodeficiency virus (FIV) or dogs on long-term immunosuppressive therapy present modified risk profiles. AAFP guidance advises against MLV vaccines in FIV-positive cats with advanced disease; killed products are preferred. Consultation with veterinary internal medicine specialists may be warranted.

Vaccine-associated sarcoma risk in cats — Feline injection-site sarcoma (FISS) is a documented adverse event with an estimated incidence of 1 in 10,000 to 1 in 30,000 vaccinations (AAFP Vaccine-Associated Sarcoma Task Force). The Vaccine-Associated Feline Sarcoma Task Force recommends the "3-2-1 rule": biopsy if a mass persists more than 3 months, exceeds 2 cm, or increases in size 1 month post-vaccination. Adjuvanted killed vaccines have historically been associated with higher FISS rates, informing preference for non-adjuvanted or recombinant products at AAFP-recommended anatomical sites (distal limb or tail base). Cases involving sarcoma require veterinary oncology referral.

Serologic titer testing — AAHA 2022 canine guidelines explicitly support titer-based decisions for CDV, CPV-2, and CAV-2 in adult dogs. A protective titer does not replace legally mandated rabies vaccination intervals under state statute.

Titer vs. booster contrast: Titer testing measures existing immunity and avoids unnecessary antigen exposure; automatic triennial boosters ensure compliance without serologic cost. Neither approach is universally superior — the choice depends on owner preference, cost, patient history, and state legal requirements for rabies specifically.

Lapsed or incomplete schedules — AAHA guidance states that interrupted series do not need to restart from dose 1 in adult dogs; vaccination resumes from the point of interruption, with dose intervals maintained.

Adverse reaction history — Documented hypersensitivity reactions, including type I (anaphylaxis) events, require pre-medication protocols, alternative product selection, or consultation with veterinary dermatology or internal medicine services. Adverse vaccine events are reportable to the USDA Center for Veter